Evidence map›Paper›PMID 33106264›Full record

ArticleAntimicrobial agents and chemotherapy2020

Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis.

Melisa Willby, Paige Chopra, Darrin Lemmer, Katherine Klein, Tracy L Dalton, David M Engelthaler, J Peter Cegielski, James E Posey, Global PETTS Investigators

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.0field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Gemifloxacin resistance inMicrobiology spectrum · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Melisa WillbyDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Paige ChopraDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Darrin LemmerTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
Katherine KleinDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Tracy L Dalton
David M EngelthalerTranslational Genomics Research Institute, Flagstaff, Arizona, USA.ORCID 0000-0001-5945-059X
J Peter CegielskiDivision of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
James E PoseyDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA hzp9@cdc.gov.ORCID 0000-0002-3901-8836
Global PETTS Investigators
Centers for Disease Control and Prevention · USTranslational Genomics Research Institute · US

Funding

Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI131939 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGELTHALER, DAVID M, METCALFE, JOHN ZAPATA · 2018 to 2023
$3.9M
NIAID NIH HHS R01 AI131939
6 · The paper itself

Abstract

Fluoroquinolones (FQ) are crucial components of multidrug-resistant tuberculosis (MDR TB) treatment. Differing levels of resistance are associated with specific mutations within the

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDNA GyraseDrug Resistance, Multiple, BacterialFluoroquinolonesHumansMicrobial Sensitivity TestsAntitubercular AgentsDNA GyraseFluoroquinolonesacquired drug resistancefluoroquinolonelevofloxacinmoxifloxacinmultidrug-resistant tuberculosisQRDR

Identifiers

PMID33106264
PMCPMC7927810
OpenAlexW3094075191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.